View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 14, 2021

Genetron and Siemens partner on lung cancer diagnosis in China

Genetron Health partners with Siemens Healthineers to promote lung cancer diagnosis and treatment in China.

Genetron Health has partnered with Siemens Healthineers to enable large-scale application of its S5 platform and lung cancer 8-gene IVD assay in hospitals in China.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The aim is to offer individualised diagnosis and treatment guidance for patients with non-small cell lung cancer (NSCLC). Genetron and Siemens intend to standardise molecular testing for cancer.

Genetron’s lung cancer 8-gene IVD assay is based on the company’s One-Step Seq technology. The test can simultaneously identify multiple mutations and fusions across eight genes, the company said.

Designed to help in the selection of targeted treatment for NSCLC, the assay enables quick and precise molecular typing, guidance on medication and tracking of drug resistance.

When used with Genetron S5, the assay has further benefits, such as detection efficiency, easy usage and a two-day turnaround time.

Genetron said that the assay can be used for independent clinical molecular testing at all levels in hospitals across China.

Genetron Health co-founder and CEO Sizhen Wang said: “We are pleased to collaborate with Siemens Healthineers for our S5 instrument and lung 8 IVD assay, which helps diagnose and treat cancer patients.

“We also expect this partnership to help standardise cancer molecular testing in China, and reach more patients in need.”

The Genetron Health portfolio includes molecular profiling tests, screening products to find cancer early and companion diagnostics.

Siemens Healthineers Greater China laboratory diagnostics vice-president Guo Yiming said: “To help Chinese cancer patients access quality care, we are not only introducing cutting-edge testing analysers and reagents to China but are also working with local innovators to offer personalised diagnostics.

“Meanwhile, we expect to push forward precision care in the field of lung cancer, therefore contributing to the vision of a healthy China.”

In June last year, Genetron Health collaborated with Thermo Fisher Scientific to expand precision cancer diagnosis and monitoring in Chinese public hospitals.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network